Persistent epigenetic signals propel a senescence-associated secretory phenotype and trained innate immunity in CD34

Cardiovascular disease Diabetes mellitus Epigenetics Hematopoietic stem cells Trained immunity

Journal

Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637

Informations de publication

Date de publication:
29 Mar 2024
Historique:
received: 17 12 2023
accepted: 11 03 2024
medline: 30 3 2024
pubmed: 30 3 2024
entrez: 30 3 2024
Statut: epublish

Résumé

Diabetes-induced trained immunity contributes to the development of atherosclerosis and its complications. This study aimed to investigate in humans whether epigenetic signals involved in immune cell activation and inflammation are initiated in hematopoietic stem/progenitor cells (HSPCs) and transferred to differentiated progeny. High glucose (HG)-exposure of cord blood (CB)-derived HSPCs induced a senescent-associated secretory phenotype (SASP) characterized by cell proliferation lowering, ROS production, telomere shortening, up-regulation of p21 and p27genes, upregulation of NFkB-p65 transcription factor and increased secretion of the inflammatory cytokines TNFα and IL6. Chromatin immunoprecipitation assay (ChIP) of p65 promoter revealed that H3K4me1 histone mark accumulation and methyltransferase SetD7 recruitment, along with the reduction of repressive H3K9me3 histone modification, were involved in NFkB-p65 upregulation of HG-HSPCs, as confirmed by increased RNA polymerase II engagement at gene level. The differentiation of HG-HSPCs into myeloid cells generated highly responsive monocytes, mainly composed of intermediate subsets (CD Hyperglycemia induces marked chromatin modifications in HSPCs, which, once transmitted to the cell progeny, contributes to persistent and pathogenic changes in immune cell function and composition.

Sections du résumé

BACKGROUND BACKGROUND
Diabetes-induced trained immunity contributes to the development of atherosclerosis and its complications. This study aimed to investigate in humans whether epigenetic signals involved in immune cell activation and inflammation are initiated in hematopoietic stem/progenitor cells (HSPCs) and transferred to differentiated progeny.
METHODS AND RESULTS RESULTS
High glucose (HG)-exposure of cord blood (CB)-derived HSPCs induced a senescent-associated secretory phenotype (SASP) characterized by cell proliferation lowering, ROS production, telomere shortening, up-regulation of p21 and p27genes, upregulation of NFkB-p65 transcription factor and increased secretion of the inflammatory cytokines TNFα and IL6. Chromatin immunoprecipitation assay (ChIP) of p65 promoter revealed that H3K4me1 histone mark accumulation and methyltransferase SetD7 recruitment, along with the reduction of repressive H3K9me3 histone modification, were involved in NFkB-p65 upregulation of HG-HSPCs, as confirmed by increased RNA polymerase II engagement at gene level. The differentiation of HG-HSPCs into myeloid cells generated highly responsive monocytes, mainly composed of intermediate subsets (CD
CONCLUSIONS CONCLUSIONS
Hyperglycemia induces marked chromatin modifications in HSPCs, which, once transmitted to the cell progeny, contributes to persistent and pathogenic changes in immune cell function and composition.

Identifiants

pubmed: 38553774
doi: 10.1186/s12933-024-02195-1
pii: 10.1186/s12933-024-02195-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107

Informations de copyright

© 2024. The Author(s).

Références

Lofblad L, Hov GG, Asberg A, Videm V. Inflammatory markers and risk of cardiovascular mortality in relation to diabetes status in the HUNT study. Sci Rep. 2021;11(1):15644.
pubmed: 34341370 pmcid: 8329190 doi: 10.1038/s41598-021-94995-8
Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505(7483):327–34.
pubmed: 24429631 pmcid: 4514480 doi: 10.1038/nature12984
Barrett TJ, Murphy AJ, Goldberg IJ, Fisher EA. Diabetes-mediated myelopoiesis and the relationship to cardiovascular risk. Ann NY Acad Sci. 2017;1402(1):31–42.
pubmed: 28926114 doi: 10.1111/nyas.13462
Nagareddy PR, Murphy AJ, Stirzaker RA, Hu Y, Yu S, Miller RG, Ramkhelawon B, Distel E, Westerterp M, Huang LS, et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab. 2013;17(5):695–708.
pubmed: 23663738 pmcid: 3992275 doi: 10.1016/j.cmet.2013.04.001
Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract. 2007;77(1):47–57.
pubmed: 17112620 doi: 10.1016/j.diabres.2006.10.007
Poller WC, Nahrendorf M, Swirski FK. Hematopoiesis and cardiovascular disease. Circ Res. 2020;126(8):1061–85.
pubmed: 32271679 pmcid: 7153537 doi: 10.1161/CIRCRESAHA.120.315895
Gallagher KA, Joshi A, Carson WF, Schaller M, Allen R, Mukerjee S, Kittan N, Feldman EL, Henke PK, Hogaboam C, et al. Epigenetic changes in bone marrow progenitor cells influence the inflammatory phenotype and alter wound healing in type 2 diabetes. Diabetes. 2015;64(4):1420–30.
pubmed: 25368099 doi: 10.2337/db14-0872
Davis FM, Gallagher KA. Epigenetic mechanisms in monocytes/macrophages regulate inflammation in cardiometabolic and vascular disease. Arterioscler Thromb Vasc Biol. 2019;39(4):623–34.
pubmed: 30760015 pmcid: 6438376 doi: 10.1161/ATVBAHA.118.312135
Siebel AL, Fernandez AZ, El-Osta A. Glycemic memory associated epigenetic changes. Biochem Pharmacol. 2010;80(12):1853–9.
pubmed: 20599797 doi: 10.1016/j.bcp.2010.06.005
Ahmed M, de Winther MPJ, Van den Bossche J. Epigenetic mechanisms of macrophage activation in type 2 diabetes. Immunobiology. 2017;222(10):937–43.
pubmed: 27613200 doi: 10.1016/j.imbio.2016.08.011
Edgar L, Akbar N, Braithwaite AT, Krausgruber T, Gallart-Ayala H, Bailey J, Corbin AL, Khoyratty TE, Chai JT, Alkhalil M, et al. Hyperglycemia induces trained immunity in macrophages and their precursors and promotes atherosclerosis. Circulation. 2021;144(12):961–82.
pubmed: 34255973 pmcid: 8448412 doi: 10.1161/CIRCULATIONAHA.120.046464
Tuano NK, Okabe J, Ziemann M, Cooper ME, El-Osta A. Set7 mediated interactions regulate transcriptional networks in embryonic stem cells. Nucleic Acids Res. 2016;44(19):9206–17.
pubmed: 27439711 pmcid: 5100561
Paneni F, Mocharla P, Akhmedov A, Costantino S, Osto E, Volpe M, Luscher TF, Cosentino F. Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes. Circ Res. 2012;111(3):278–89.
pubmed: 22693349 doi: 10.1161/CIRCRESAHA.112.266593
El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008;205(10):2409–17.
pubmed: 18809715 pmcid: 2556800 doi: 10.1084/jem.20081188
Okabe J, Orlowski C, Balcerczyk A, Tikellis C, Thomas MC, Cooper ME, El-Osta A. Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circ Res. 2012;110(8):1067–76.
pubmed: 22403242 doi: 10.1161/CIRCRESAHA.112.266171
Paneni F, Volpe M, Luscher TF, Cosentino F. SIRT1, p66(Shc), and Set7/9 in vascular hyperglycemic memory: bringing all the strands together. Diabetes. 2013;62(6):1800–7.
pubmed: 23704521 pmcid: 3661615 doi: 10.2337/db12-1648
Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: the “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009;94(2):410–5.
pubmed: 19066300 doi: 10.1210/jc.2008-1824
Vigorelli V, Resta J, Bianchessi V, Lauri A, Bassetti B, Agrifoglio M, Pesce M, Polvani G, Bonalumi G, Cavallotti L, et al. Abnormal DNA methylation induced by hyperglycemia reduces CXCR 4 gene expression in CD 34(+) stem cells. J Am Heart Assoc. 2019;8(9): e010012.
pubmed: 31018749 pmcid: 6512087 doi: 10.1161/JAHA.118.010012
Sun Y, Wang X, Liu T, Zhu X, Pan X. The multifaceted role of the SASP in atherosclerosis: from mechanisms to therapeutic opportunities. Cell Biosci. 2022;12(1):74.
pubmed: 35642067 pmcid: 9153125 doi: 10.1186/s13578-022-00815-5
Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden JE, Premsrirut P, Luo W, Chicas A, Lee CS, et al. Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev. 2011;25(20):2125–36.
pubmed: 21979375 pmcid: 3205583 doi: 10.1101/gad.17276711
Paneni F, Costantino S, Battista R, Castello L, Capretti G, Chiandotto S, Scavone G, Villano A, Pitocco D, Lanza G, et al. Adverse epigenetic signatures by histone methyltransferase Set7 contribute to vascular dysfunction in patients with type 2 diabetes mellitus. Circ Cardiovasc Genet. 2015;8(1):150–8.
pubmed: 25472959 doi: 10.1161/CIRCGENETICS.114.000671
Rothgiesser KM, Erener S, Waibel S, Luscher B, Hottiger MO. Correction: SIRT2 regulates NF-kappaB-dependent gene expression through deacetylation of p65 Lys310. J Cell Sci. 2019;132(8):4251. https://doi.org/10.1242/jcs.073783 .
doi: 10.1242/jcs.073783
Moroni F, Ammirati E, Norata GD, Magnoni M, Camici PG. The role of monocytes and macrophages in human atherosclerosis, plaque neoangiogenesis, and atherothrombosis. Mediators Inflamm. 2019;2019:7434376.
pubmed: 31089324 pmcid: 6476044 doi: 10.1155/2019/7434376
Mandl M, Schmitz S, Weber C, Hristov M. Characterization of the CD14++CD16+ monocyte population in human bone marrow. PLoS ONE. 2014;9(11): e112140.
pubmed: 25369328 pmcid: 4219836 doi: 10.1371/journal.pone.0112140
Min D, Brooks B, Wong J, Salomon R, Bao W, Harrisberg B, Twigg SM, Yue DK, McLennan SV. Alterations in monocyte CD16 in association with diabetes complications. Mediators Inflamm. 2012;2012: 649083.
pubmed: 23316106 pmcid: 3536440 doi: 10.1155/2012/649083
Rogacev KS, Cremers B, Zawada AM, Seiler S, Binder N, Ege P, Grosse-Dunker G, Heisel I, Hornof F, Jeken J, et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol. 2012;60(16):1512–20.
pubmed: 22999728 doi: 10.1016/j.jacc.2012.07.019
Stec M, Weglarczyk K, Baran J, Zuba E, Mytar B, Pryjma J, Zembala M. Expansion and differentiation of CD14+CD16(-) and CD14+ +CD16+ human monocyte subsets from cord blood CD34+ hematopoietic progenitors. J Leukoc Biol. 2007;82(3):594–602.
pubmed: 17595380 doi: 10.1189/jlb.0207117
Okdahl T, Wegeberg AM, Pociot F, Brock B, Storling J, Brock C. Low-grade inflammation in type 2 diabetes: a cross-sectional study from a Danish diabetes outpatient clinic. BMJ Open. 2022;12(12): e062188.
pubmed: 36517105 pmcid: 9756179 doi: 10.1136/bmjopen-2022-062188
Group AS, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818–28.
doi: 10.1056/NEJMoa1006524
Newman JD, Vani AK, Aleman JO, Weintraub HS, Berger JS, Schwartzbard AZ. The changing landscape of diabetes therapy for cardiovascular risk reduction: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(15):1856–69.
pubmed: 30286929 pmcid: 6178226 doi: 10.1016/j.jacc.2018.07.071
Cryer PE. Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med. 2011;124(11):993–6.
pubmed: 22017775 pmcid: 3464092 doi: 10.1016/j.amjmed.2011.08.008
Sharif S, Van der Graaf Y, Cramer MJ, Kapelle LJ, de Borst GJ, Visseren FLJ, Westerink J, group Ss. Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):220.
pubmed: 34753497 pmcid: 8579639 doi: 10.1186/s12933-021-01409-0
Miller RG, Orchard TJ. Understanding metabolic memory: a tale of two studies. Diabetes. 2020;69(3):291–9.
pubmed: 32079705 pmcid: 7034186 doi: 10.2337/db19-0514
Jayaraman S. Epigenetic mechanisms of metabolic memory in diabetes. Circ Res. 2012;110(8):1039–41.
pubmed: 22499895 doi: 10.1161/CIRCRESAHA.112.268375
Keating ST, Plutzky J, El-Osta A. Epigenetic changes in diabetes and cardiovascular risk. Circ Res. 2016;118(11):1706–22.
pubmed: 27230637 pmcid: 5593074 doi: 10.1161/CIRCRESAHA.116.306819
Diabetes C, Complications Trial Research G, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.
doi: 10.1056/NEJM199309303291401
Writing Team for the Diabetes C, Complications Trial/Epidemiology of Diabetes I, Complications Research G. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the epidemiology of diabetes interventions and complications (EDIC) study. JAMA. 2003;290(16):2159–67.
doi: 10.1001/jama.290.16.2159
Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajanirefah A, Matarese F, Cheng SC, Ratter J, Berentsen K, van der Ent MA, et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science. 2014;345(6204):1251086.
pubmed: 25258085 pmcid: 4242194 doi: 10.1126/science.1251086
Terenzi DC, Al-Omran M, Quan A, Teoh H, Verma S, Hess DA. Circulating pro-vascular progenitor cell depletion during type 2 diabetes: translational insights into the prevention of ischemic complications in diabetes. JACC Basic Transl Sci. 2019;4(1):98–112.
pubmed: 30847424 doi: 10.1016/j.jacbts.2018.10.005
van Diepen JA, Thiem K, Stienstra R, Riksen NP, Tack CJ, Netea MG. Diabetes propels the risk for cardiovascular disease: sweet monocytes becoming aggressive? Cell Mol Life Sci. 2016;73(24):4675–84.
pubmed: 27469259 pmcid: 5097107 doi: 10.1007/s00018-016-2316-9
Fadini GP, Avogaro A. It is all in the blood: the multifaceted contribution of circulating progenitor cells in diabetic complications. Exp Diabetes Res. 2012;2012: 742976.
pubmed: 22548049 pmcid: 3324138 doi: 10.1155/2012/742976
Kojima H, Kim J, Chan L. Emerging roles of hematopoietic cells in the pathobiology of diabetic complications. Trends Endocrinol Metab. 2014;25(4):178–87.
pubmed: 24507996 pmcid: 3975817 doi: 10.1016/j.tem.2014.01.002
Yan J, Tie G, Wang S, Tutto A, DeMarco N, Khair L, Fazzio TG, Messina LM. Diabetes impairs wound healing by Dnmt1-dependent dysregulation of hematopoietic stem cells differentiation towards macrophages. Nat Commun. 2018;9(1):33.
pubmed: 29295997 pmcid: 5750226 doi: 10.1038/s41467-017-02425-z
Barman PK, Urao N, Koh TJ. Diabetes induces myeloid bias in bone marrow progenitors associated with enhanced wound macrophage accumulation and impaired healing. J Pathol. 2019;249(4):435–46.
pubmed: 31342513 pmcid: 8212828 doi: 10.1002/path.5330
Keating ST, Groh L, van der Heijden C, Rodriguez H, Dos Santos JC, Fanucchi S, Okabe J, Kaipananickal H, van Puffelen JH, Helder L, et al. The Set7 lysine methyltransferase regulates plasticity in oxidative phosphorylation necessary for trained immunity induced by beta-glucan. Cell Rep. 2020;31(3): 107548.
pubmed: 32320649 pmcid: 7184679 doi: 10.1016/j.celrep.2020.107548
Zatterale F, Raciti GA, Prevenzano I, Leone A, Campitelli M, De Rosa V, Beguinot F, Parrillo L. Epigenetic reprogramming of the inflammatory response in obesity and type 2 diabetes. Biomolecules. 2022;12(7):982.
pubmed: 35883538 pmcid: 9313117 doi: 10.3390/biom12070982
Choudhury RP, Edgar L, Ryden M, Fisher EA. Diabetes and metabolic drivers of trained immunity: new therapeutic targets beyond glucose. Arterioscler Thromb Vasc Biol. 2021;41(4):1284–90.
pubmed: 33657881 pmcid: 10069665 doi: 10.1161/ATVBAHA.120.314211
Nelson G, Kucheryavenko O, Wordsworth J, von Zglinicki T. The senescent bystander effect is caused by ROS-activated NF-kappaB signalling. Mech Ageing Dev. 2018;170:30–6.
pubmed: 28837845 pmcid: 5861994 doi: 10.1016/j.mad.2017.08.005
Kowluru RA, Koppolu P, Chakrabarti S, Chen S. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic Res. 2003;37(11):1169–80.
pubmed: 14703729 doi: 10.1080/10715760310001604189
Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, Natarajan R. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA. 2008;105(26):9047–52.
pubmed: 18579779 pmcid: 2449362 doi: 10.1073/pnas.0803623105
Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK, Calkin AC, Brownlee M, Cooper ME, El-Osta A. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes. 2009;58(5):1229–36.
pubmed: 19208907 pmcid: 2671038 doi: 10.2337/db08-1666
Huang B, Yang XD, Zhou MM, Ozato K, Chen LF. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol. 2009;29(5):1375–87.
pubmed: 19103749 doi: 10.1128/MCB.01365-08
Scisciola L, Rizzo MR, Cataldo V, Fontanella RA, Balestrieri ML, D’Onofrio N, Marfella R, Paolisso G, Barbieri M. Incretin drugs effect on epigenetic machinery: new potential therapeutic implications in preventing vascular diabetic complications. FASEB J. 2020;34(12):16489–503.
pubmed: 33090591 doi: 10.1096/fj.202000860RR
Sforza A, Vigorelli V, Rurali E, Perrucci GL, Gambini E, Arici M, Metallo A, Rinaldi R, Fiorina P, Barbuti A, et al. Liraglutide preserves CD34(+) stem cells from dysfunction Induced by high glucose exposure. Cardiovasc Diabetol. 2022;21(1):51.
pubmed: 35397526 pmcid: 8994898 doi: 10.1186/s12933-022-01486-9
Marino F, Scalise M, Salerno N, Salerno L, Molinaro C, Cappetta D, Torella M, Greco M, Foti D, Sasso FC, et al. Diabetes-induced cellular senescence and senescence-associated secretory phenotype impair cardiac regeneration and function independently of age. Diabetes. 2022;71(5):1081–98.
pubmed: 35108360 pmcid: 9490451 doi: 10.2337/db21-0536
D’Alessandra Y, Chiesa M, Vigorelli V, Ricci V, Rurali E, Raucci A, Colombo GI, Pompilio G, Vinci MC. Diabetes induces a transcriptional signature in bone marrow-derived CD34(+) hematopoietic stem cells predictive of their progeny dysfunction. Int J Mol Sci. 2021;22(3):1423.
pubmed: 33572602 pmcid: 7866997 doi: 10.3390/ijms22031423
Vinci MC, Gambini E, Bassetti B, Genovese S, Pompilio G. When good guys turn bad: bone marrow’s and hematopoietic stem cells’ role in the pathobiology of diabetic complications. Int J Mol Sci. 2020;21(11):3864.
pubmed: 32485847 pmcid: 7312629 doi: 10.3390/ijms21113864
Costantino S, Paneni F, Battista R, Castello L, Capretti G, Chiandotto S, Tanese L, Russo G, Pitocco D, Lanza GA, et al. Impact of glycemic variability on chromatin remodeling, oxidative stress, and endothelial dysfunction in patients with type 2 diabetes and with target HbA(1c) Levels. Diabetes. 2017;66(9):2472–82.
pubmed: 28634176 doi: 10.2337/db17-0294
Ambrosini S, Montecucco F, Kolijn D, Pedicino D, Akhmedov A, Mohammed SA, Herwig M, Gorica E, Szabo PL, Weber L, et al. Methylation of the Hippo effector YAP by the methyltransferase SETD7 drives myocardial ischaemic injury: a translational study. Cardiovasc Res. 2023;118(17):3374–85.
pubmed: 35709329 doi: 10.1093/cvr/cvac102

Auteurs

Maria Cristina Vinci (MC)

Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino IRCCS, Via C. Parea 4, 20138, Milan, Italy. cristina.vinci@ccfm.it.

Sarah Costantino (S)

Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zurich and University of Zürich, Zurich, Switzerland.
University Heart Center, University Hospital Zurich, Zurich, Switzerland.

Giulia Damiano (G)

Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino IRCCS, Via C. Parea 4, 20138, Milan, Italy.

Erica Rurali (E)

Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino IRCCS, Via C. Parea 4, 20138, Milan, Italy.

Raffaella Rinaldi (R)

Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino IRCCS, Via C. Parea 4, 20138, Milan, Italy.

Vera Vigorelli (V)

Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino IRCCS, Via C. Parea 4, 20138, Milan, Italy.

Annalisa Sforza (A)

Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino IRCCS, Via C. Parea 4, 20138, Milan, Italy.

Ermes Carulli (E)

Dipartimento Di Scienze Cliniche E Di Comunità, Università Di Milano, Milan, Italy.
Doctoral Programme in Translational Medicine, Università Di Milano, 20122, Milan, Italy.

Sergio Pirola (S)

Department of Cardiac Surgery, Centro Cardiologico Monzino IRCCS, Milan, Italy.

Giorgio Mastroiacovo (G)

Department of Cardiac Surgery, Centro Cardiologico Monzino IRCCS, Milan, Italy.

Angela Raucci (A)

Unit of Experimental Cardio-Oncology and Cardiovascular Aging, Centro Cardiologico Monzino IRCCS, Milan, Italy.

Assam El-Osta (A)

Epigenetics in Human Health and Disease Program, Baker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia.

Francesco Paneni (F)

Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zurich and University of Zürich, Zurich, Switzerland. francesco.paneni@uzh.ch.
University Heart Center, University Hospital Zurich, Zurich, Switzerland. francesco.paneni@uzh.ch.

Giulio Pompilio (G)

Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino IRCCS, Via C. Parea 4, 20138, Milan, Italy.
Department of Biomedical, Surgical and Dental Sciences, Università Degli Studi di Milano, Milan, Italy.

Classifications MeSH